Evolus, Inc. (0K16.L)
USD 14.58
(0.16%)
USD 14.58
(0.16%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 209.68 Million USD | 31.48% |
| 2022 | 159.48 Million USD | -9.18% |
| 2021 | 175.6 Million USD | -37.73% |
| 2020 | 282.02 Million USD | 75.19% |
| 2019 | 160.98 Million USD | 84.07% |
| 2018 | 87.46 Million USD | -61.6% |
| 2017 | 227.77 Million USD | 169.24% |
| 2016 | 84.6 Million USD | 22.08% |
| 2015 | 69.29 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 207.73 Million USD | -0.93% |
| 2024 Q2 | 214.45 Million USD | 3.24% |
| 2023 Q3 | 187.33 Million USD | 6.48% |
| 2023 Q4 | 209.68 Million USD | 11.93% |
| 2023 FY | 209.68 Million USD | 31.48% |
| 2023 Q1 | 153.28 Million USD | -3.89% |
| 2023 Q2 | 175.94 Million USD | 14.78% |
| 2022 FY | 159.48 Million USD | -9.18% |
| 2022 Q3 | 163.49 Million USD | -0.34% |
| 2022 Q4 | 159.48 Million USD | -2.46% |
| 2022 Q2 | 164.05 Million USD | 6.94% |
| 2022 Q1 | 153.41 Million USD | -12.64% |
| 2021 Q3 | 117.81 Million USD | -11.9% |
| 2021 FY | 175.6 Million USD | -37.73% |
| 2021 Q2 | 133.72 Million USD | -0.14% |
| 2021 Q1 | 133.9 Million USD | -52.52% |
| 2021 Q4 | 175.6 Million USD | 49.05% |
| 2020 FY | 282.02 Million USD | 75.19% |
| 2020 Q1 | 151.54 Million USD | -5.86% |
| 2020 Q2 | 150.94 Million USD | -0.4% |
| 2020 Q3 | 180.68 Million USD | 19.71% |
| 2020 Q4 | 282.02 Million USD | 56.09% |
| 2019 Q1 | 145.57 Million USD | 66.44% |
| 2019 FY | 160.98 Million USD | 84.07% |
| 2019 Q4 | 160.98 Million USD | -2.8% |
| 2019 Q3 | 165.62 Million USD | 2.49% |
| 2019 Q2 | 161.6 Million USD | 11.01% |
| 2018 Q3 | 88.41 Million USD | 5.25% |
| 2018 FY | 87.46 Million USD | -61.6% |
| 2018 Q2 | 83.99 Million USD | 11.39% |
| 2018 Q1 | 75.41 Million USD | -66.89% |
| 2018 Q4 | 87.46 Million USD | -1.08% |
| 2017 FY | 227.77 Million USD | 169.24% |
| 2017 Q1 | - USD | -100.0% |
| 2017 Q2 | 213.14 Million USD | 0.0% |
| 2017 Q3 | 94.51 Million USD | -55.66% |
| 2017 Q4 | 227.77 Million USD | 140.99% |
| 2016 FY | 84.6 Million USD | 22.08% |
| 2016 Q4 | 84.6 Million USD | 0.0% |
| 2015 FY | 69.29 Million USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| uniQure N.V. | 624.01 Million USD | 66.397% |
| Agios Pharmaceuticals, Inc. | 126.09 Million USD | -66.288% |
| Amicus Therapeutics, Inc. | 617.7 Million USD | 66.054% |
| Atara Biotherapeutics, Inc. | 264.73 Million USD | 20.794% |
| bluebird bio, Inc. | 424.62 Million USD | 50.618% |
| Cara Therapeutics, Inc. | 68.75 Million USD | -204.959% |
| Imunon, Inc. | 8.53 Million USD | -2358.107% |
| Editas Medicine, Inc. | 150.05 Million USD | -39.739% |
| IQVIA Holdings Inc. | 20.56 Billion USD | 98.981% |
| Mettler-Toledo International Inc. | 3.5 Billion USD | 94.018% |
| Myriad Genetics, Inc. | 312.9 Million USD | 32.986% |
| Neurocrine Biosciences, Inc. | 1.01 Billion USD | 79.43% |
| Supernus Pharmaceuticals, Inc. | 487.46 Million USD | 56.984% |
| Verastem, Inc. | 71.18 Million USD | -194.566% |
| Walgreens Boots Alliance, Inc. | 68.85 Billion USD | 99.695% |
| Waters Corporation | 3.47 Billion USD | 93.968% |
| Thermo Fisher Scientific Inc. | 51.88 Billion USD | 99.596% |
| Biogen Inc. | 12.04 Billion USD | 98.259% |
| Nektar Therapeutics | 267.04 Million USD | 21.479% |
| Perrigo Company plc | 6.04 Billion USD | 96.529% |
| Dynavax Technologies Corporation | 375.02 Million USD | 44.087% |
| Illumina, Inc. | 4.36 Billion USD | 95.197% |
| Corbus Pharmaceuticals Holdings, Inc. | 35.17 Million USD | -496.089% |
| Iovance Biotherapeutics, Inc. | 195.73 Million USD | -7.126% |
| Heron Therapeutics, Inc. | 256.47 Million USD | 18.244% |
| Unity Biotechnology, Inc. | 37.29 Million USD | -462.284% |
| BioMarin Pharmaceutical Inc. | 1.89 Billion USD | 88.906% |
| Sangamo Therapeutics, Inc. | 82.43 Million USD | -154.373% |
| Adicet Bio, Inc. | 37.12 Million USD | -464.89% |
| Aclaris Therapeutics, Inc. | 40.22 Million USD | -421.272% |
| Regeneron Pharmaceuticals, Inc. | 7.1 Billion USD | 97.05% |
| Esperion Therapeutics, Inc. | 660.79 Million USD | 68.267% |
| FibroGen, Inc. | 585.72 Million USD | 64.201% |
| Agilent Technologies, Inc. | 4.91 Billion USD | 95.736% |
| OPKO Health, Inc. | 622.47 Million USD | 66.314% |
| Homology Medicines, Inc. | 118.53 Million USD | -76.902% |
| Geron Corporation | 146.12 Million USD | -43.496% |
| Alnylam Pharmaceuticals, Inc. | 4.05 Billion USD | 94.823% |
| Exelixis, Inc. | 678.44 Million USD | 69.093% |
| Viking Therapeutics, Inc. | 20.07 Million USD | -944.726% |
| Anavex Life Sciences Corp. | 12.53 Million USD | -1572.946% |
| Intellia Therapeutics, Inc. | 250.8 Million USD | 16.395% |
| Zoetis Inc. | 9.29 Billion USD | 97.744% |
| Axsome Therapeutics, Inc. | 397.25 Million USD | 47.217% |
| Abeona Therapeutics Inc. | 49.17 Million USD | -326.401% |
| Vertex Pharmaceuticals Incorporated | 5.14 Billion USD | 95.928% |
| Kala Pharmaceuticals, Inc. | 48.44 Million USD | -332.835% |
| Ionis Pharmaceuticals, Inc. | 2.6 Billion USD | 91.946% |
| Sarepta Therapeutics, Inc. | 2.4 Billion USD | 91.282% |
| Corcept Therapeutics Incorporated | 114.81 Million USD | -82.635% |
| Halozyme Therapeutics, Inc. | 1.64 Billion USD | 87.288% |
| Blueprint Medicines Corporation | 918.64 Million USD | 77.174% |
| Insmed Incorporated | 1.66 Billion USD | 87.382% |
| TG Therapeutics, Inc. | 169.08 Million USD | -24.013% |
| Incyte Corporation | 1.59 Billion USD | 86.831% |
| Emergent BioSolutions Inc. | 1.18 Billion USD | 82.314% |